Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Patient-related outcome shows strong link to survival in PAH

Patient-related outcome shows strong link to survival in PAH

Pathophysiological biomarkers predict PAH prognosis

Pathophysiological biomarkers predict PAH prognosis

CV risk assessment essential for CML TKI trial design

CV risk assessment essential for CML TKI trial design

Algorithm reduces PAH screening costs in systemic sclerosis patients

Algorithm reduces PAH screening costs in systemic sclerosis patients

6-minute walk ‘not an accurate surrogate’ in systemic sclerosis-associated PAH

6-minute walk ‘not an accurate surrogate’ in systemic sclerosis-associated PAH

Scientists compile complete genetic information of people affected by PAH

Scientists compile complete genetic information of people affected by PAH

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Upfront combination therapy fulfils AMBITION in PAH patients

Upfront combination therapy fulfils AMBITION in PAH patients

PAH treatments less effective in CTD-associated disease

PAH treatments less effective in CTD-associated disease

New treatment algorithm for pulmonary arterial hypertension launched in 2015 ESC/ERS Guidelines

New treatment algorithm for pulmonary arterial hypertension launched in 2015 ESC/ERS Guidelines

Optimal aerobic exercise training may benefit patients with pulmonary arterial hypertension

Optimal aerobic exercise training may benefit patients with pulmonary arterial hypertension

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Novel treatment target found for RV failure in PAH

Novel treatment target found for RV failure in PAH

Low GLSRV heralds adverse outcomes in PAH patients

Low GLSRV heralds adverse outcomes in PAH patients

Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)